Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verastem (VSTM) Cash & Equivalents (2018 - 2025)

Verastem has reported Cash & Equivalents over the past 8 years, most recently at $205.0 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $205.0 million for Q4 2025, up 130.8% from a year ago — trailing twelve months through Dec 2025 was $205.0 million (up 130.8% YoY), and the annual figure for FY2025 was $205.0 million, up 130.8%.
  • Cash & Equivalents for Q4 2025 was $205.0 million at Verastem, up from $137.7 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for VSTM hit a ceiling of $205.0 million in Q4 2025 and a floor of $24.3 million in Q3 2021.
  • Median Cash & Equivalents over the past 5 years was $82.3 million (2024), compared with a mean of $93.6 million.
  • Biggest five-year swings in Cash & Equivalents: plummeted 85.74% in 2021 and later soared 221.49% in 2022.
  • Verastem's Cash & Equivalents stood at $74.8 million in 2021, then rose by 5.73% to $79.1 million in 2022, then fell by 1.48% to $77.9 million in 2023, then grew by 14.0% to $88.8 million in 2024, then skyrocketed by 130.8% to $205.0 million in 2025.
  • The last three reported values for Cash & Equivalents were $205.0 million (Q4 2025), $137.7 million (Q3 2025), and $164.3 million (Q2 2025) per Business Quant data.